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Abstract. The WHO recommends mass treatment with praziquantel as the primary approach for Schistosoma
mansoni–related morbidity control in endemic populations. The Schistosomiasis Consortium for Operational Research
and Evaluation implemented multi-country, cluster-randomized trials to compare effectiveness of community-wide and
school-based treatment (SBT) regimens on prevalence and intensity of schistosomiasis. To assess the impact of two
different treatment schedules on S. mansoni–associated morbidity in children, cohort studies were nested within the
randomized trials conducted in villages in Kenya and Tanzania having baseline prevalence ³ 25%. Children aged 7–8
years were enrolled at baseline and followed to ages 11–12 years. Infection intensity and odds of infection were reduced
both in villages receiving four years of annual community-wide treatment (CWT) and thosewho receivedbiennial SBTover
4 years. These regimens were also associated with reduced odds of undernutrition and reduced odds of portal vein
dilation at follow-up. However, neither hemoglobin levels nor the prevalence of the rare abnormal patternC liver scores on
ultrasound improved. For the combined cohorts, growth stunting worsened in the areas receiving biennial SBT, and
maximal oxygen uptake as estimated by ﬁtness testing scores declined under both regimens. After adjusting for im-
balance in starting prevalence between study arms, children in villages receiving annual CWT had signiﬁcantly greater
decreases in infection prevalence and intensity than those villages receiving biennial SBT. Although health-related
quality-of-life scores improved in both study arms, children in the CWT villages gained signiﬁcantly more. We conclude
that programs using annual CWTare likely to achieve better overallS.mansonimorbidity control than those implementing
only biennial SBT.
INTRODUCTION
Schistosomiasis remains a major public health problem in
much of Africa. The clinical consequences of Schistosoma
mansoni infections result from tissue damage and blood loss
caused by schistosome eggs trapped in host tissues.1
Chronic immunologic reactions to the eggs cause granuloma
formation in the intestines, liver, and spleen and can progress
to cause hepatic and splenic enlargement, periportal ﬁbrosis,
portal hypertension, and esophageal varices.2 Other impacts
of infection, particularly in children, include anemia, malnutri-
tion, impaired growth, impaired cognitive development, and
generalized body weakness.1,3
Current WHO guidelines call for mass treatment with pra-
ziquantel in endemic communities to achieve morbidity
control.4–6 However, questions remain about optimal
programmatic implementation of mass drug administra-
tion (MDA).
The overall goal of the Schistosomiasis Consortium for
Operational Research and Evaluation (SCORE) project
(https://score.uga.edu/) is to provide an evidence base for
programmatic decision-making related to control and elimi-
nation of schistosomiasis.7 Among the studies in the SCORE
portfolio were multi-arm, multi-year, randomized intervention
trials that assessed changes in prevalence and intensity of
schistosomiasis in children aged 9–12 years in villages re-
ceiving MDA using different strategies over a 4-year in-
tervention period.7 The results from the randomized trials in
Kenya and Tanzania have been reported elsewhere.8,9
These longitudinal studies also provided an opportunity to
explore the impact of MDA on schistosomiasis-associated
morbidity in children.10 Therefore, SCORE nested cohort
studies of morbidity within intervention trials in Kenya and
Tanzania that were occurring in villages that had prevalence
of ³ 25% S. mansoni infection during village eligibility test-
ing.10 The treatment regimens in the two study arms that
included cohorts were either 1) 4 years of annual community-
wide treatment (CWT) or 2) every-other-year school-based
treatment (SBT) (Figure 1). In the present analysis, we com-
bined the data from the S. mansoni cohorts in Kenya and
Tanzania to assess and compare the impact of the two regi-
mens on a range of infection-associated morbidity markers.
Although results of analysis of the Kenya cohort11 and the
baseline data from the Tanzania cohort12 have been pre-
viously published, the present secondary analysis, combining
the Kenya and Tanzania data, increases the statistical power
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to detect signiﬁcant differences between CWT and SBT regi-
mens. The current studydescribes changes in anthropometric
growth indices, hemoglobin (Hb) levels, measures of physical
ﬁtness, and quality of life, aswell as the liver abnormalities and
portal vein ﬁndings among study cohort children (aged 7–8
years at baseline) at the end of their 4-year study participa-
tion.10 Our hypothesis was that annual CWTwith praziquantel
could provide incremental health beneﬁts in terms of reduc-
tions in observedmorbiditywhen comparedwith the effects of
every-other-year treatment administered in a school-based
program.10
MATERIALS AND METHODS
Ethics statement on subject recruitment. Approval for
the SCORE in Kenya and Tanzania intervention studies (the
“gaining control” studies) and their related cohort studies was
obtained from the Institutional Review Boards at the Kenya
Medical Research Institute (Nairobi, Kenya), the Centers for
Disease Control and Prevention (Georgia), and the Medical
ResearchCoordination Committee of theNational Institute for
Medical Research (Tanzania). Trials Registration numbers are
ISRCT 16755535 (Kenya) and ISRCT 95819193 (Tanzania).7
Only children who assented to participate and had written
informed consent from parents or their legally authorized
representativeswere eligible for inclusion. Before examination
and sample collection, the reason for the survey and the
procedures for sample collection were explained to the chil-
dren and the adult population in the communities, as well as
local leaders, school administrators, teachers, and health and
education personnel.
Study area and population. The results reported in this
article are a secondary analysis of data combined fromparallel
cohort studies that took place in the Nyanza region (Siaya,
Kisumu, and HomaBay counties) of Kenya13 and theMwanza
region (Misungwi and Sengerema districts) of Tanzania,9 both
ofwhich have high prevalence ofS.mansoni. All study villages
were located on or near the Lake Victoria shoreline.
The cohort study design is described in detail in earlier
articles.10,12,14 Brieﬂy, the cohort studieswere nested in larger
intervention trials on gaining control of schistosomiasis
mansoni in moderate- to high-risk communities. In these
parent SCORE intervention trials, 150 villages per country
were randomized to one of six treatment arms and givenMDA
using different approaches (CWT versus SBT) at different
frequencies (either two or four treatments) over a 4-year pe-
riod.7 Villages for inclusion in the nested cohort studies
reported in this article came from the 25 villages in the treat-
ment arm with annual CWT (the most intense treatment arm)
and the 25 villages with every-other-year SBT (a less intense
treatment arm) (see Figure 1 for ﬂow diagram).10 To achieve
the target of enrolling 800 7–8-year-old children in each
country, Tanzania included three of the 25 villages in the an-
nual CWT arm and four of the 25 in the biennial SBT arm,
whereas Kenya included six villages from each arm.10 Para-
sitologic andmorbidity parametersweremeasuredat baseline
and inYear 5, andalthoughsomemeasuresweremade inYear
3, these were not uniform between sites and are not included
in the present analysis. In years when villages were scheduled
to receive treatment, the protocol called for efforts to treat all
village school-age children, whether in school or not, and
irrespective of their egg-positive or egg-negative status. In
CWT villages, schools were used as a supplemental venue to
locate children not found at home. In SBT villages, community
mobilization teams were used to encourage parents to have
their children who were not attending school come to receive
treatment at the school on a subsequent day. During prazi-
quantel drug holiday years, children having symptoms could
seek evaluation and treatment at health facilities, which
sometimes were able to provide individual praziquantel
treatment. However, few, if any, children received treatment
during drug holiday years. There was no untreated compari-
son group.Only those childrenwhoparticipated in bothYear 1
and Year 5 are included in the analyses presented in this
article.
Data on parasitology and morbidity. The methods for the
collection of cohort data are described in detail elsewhere12,14
but are brieﬂy presented in the following paragraphs.
Stool sample collection and examination. Participants pro-
vided stool specimens on each of three consecutive days.
Duplicate Kato–Katz thick smears were made with a 41.7-mg
template15 from each specimen and examined for S. mansoni
eggs by trained microscopists.
Blood collection andHb assessment.A5-mL tubewas used
to collect 2–3 mL of venous blood sample (Kenya) or a ﬁnger-
prick blood sample (Tanzania) was collected from each indi-
vidual, and the Hb level was measured using a portable
HemoCue photometer (HemoCue, Inc., A¨ngelholm, Sweden).
The Hb level was reported in gm/dL, and ﬁnal values used in
analysis were adjusted for altitude (ca. 1,000 m) by subtracting
2 gm/dL from the raw values for both study sites.16 Anemia
wasdeﬁnedasHbvalues<11.5gm/dL forchildrenyounger than
12 years and Hb < 12 gm/dL for children of 12 years and older
but younger than 15 years, according to theWHOguidelines.17
FIGURE 1. Flowdiagramof the cohort study. In the upper arm, children lived in communities randomized to receive annual community-widemass
drug administration treatment (CWT). The children in the lower study arm lived in communities randomized to receive only biennial (every other year)
school-based treatment (SBT), with drug “holidays” in Year 2 and in Year 4. Final assessment for both groupswas performed in Year 5 of the study.
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Anthropometric measurements. Height was measured for
barefoot children using a wooden stadiometer. The child
looked straight ahead while standing on the base of the sta-
diometerwith their heels, buttocks, shoulder blades, andback
of the head touching the vertical backboard. Once the child
was correctly positioned, the stadiometer head plate was
lowered and the height measured in centimeters to one dec-
imal place. Weight was measured on a digital scale in kilo-
grams to one decimal place for barefoot children after excess
clothing was removed. Height and weight were measured
twiceby the sameexaminer and themeanvaluewas recorded.
Z-scores were calculated using WHO AnthroPlus software
(available at https://www.who.int/growthref/tools/en/) based
on the WHO growth reference data tables for 5–19-year-old
children.18 In Tanzania, the exact birthdays of some children
(and hence, their exact age in days) were not known. For such
cases, the midpoint of the Z-score limits was used, for ex-
ample, for children reported to be 7 years old, the Z-score for
children aged 7 years and 6 months was used. Wasting was
deﬁned as a body mass index-for-age Z-score of £ −2 and
stunting as a height-for-age Z-score £ −2.
Physical ﬁtness. Physical ﬁtness was assessed using the
20-m shuttle run ﬁtness test (20mSRT) as described by Bus-
tinduyet al.19 Inbrief, during the test, children runcontinuously
between two lines that are 20 m apart.20,21 A run from one line
to the other is considered a shuttle. There are 21 levels in the
test, and the higher the level, the greater the number of shut-
tles and faster the pace required to complete it. The running
ﬁeld was prepared in the school compound and runners were
laterally separated by at least 1 m. Recorders were placed at
each end of the ﬁeld, and every recorder was responsible for
monitoring three to ﬁve children. The recorder noted the level
at which the test subject stopped and how many shuttles the
child had completed within that level. These numbers were
converted to amaximal oxygen uptake, the VO2max (maximal
oxygen uptake as estimated by ﬁtness testing), in mL/kg/
minute, as previously described.22,23
Quality of life. Quality of life was assessed using the Pedi-
atric Quality of Life Inventory instrument (PedsQL) for
children,24,25 which, although developed in the Unites States,
has been validated for health-related quality-of-life assess-
ment in the East African setting.12,14,26,27 Kenya used a 23-
question version of thePedsQLsurvey,14 andTanzania used a
16-question version, but discarded the last question because
of irrelevance to the local setting.10,12 The PedsQL question-
naire is divided into four parts, with three to six questions in
each section. The four parts describe four dimensions of
functioning: 1) problems with physical activity (physical), 2)
problems with feelings (emotional), 3) problems with getting
along with others (social), and 4) problems with keeping up in
school (school). The answers are scored on a Likert-like scale
from0 to 4,where 0 is never, 1 is almost never, 2 is sometimes,
3 is often, and 4 is almost always. Responses are transformed
to scores that range from 0 to 100, with higher scores in-
dicating a better perceived quality of life.
Abdominal ultrasonography. Abdominal ultrasound was
performed using portable ultrasound machines (Aloka Sono-
camera SSD-500 with a 3.5 MHz curvilinear probe, Hitachi
Aloka Medical America, Wallingford, CT) in both Kenya and
Tanzania. The examinations were performed according to the
WHO’s Niamey protocol for imaging schistosomiasis28 by
senior sonographers with extensive experience in the ﬁeld of
ultrasonography of S. mansoni–infected individuals. Children
were examined while lying on their backs on an examination
table with their legs extended. Measurements included length
of the left liver lobe (mm), spleen length (mm), portal branch
thickness, and portal-vein diameter. The liver image was
scored as one of six patterns, A–F, as described in the WHO
protocol.28 Image patterns A and B are considered normal or
nonspeciﬁc. Image patterns C and D are considered charac-
teristic of mild and moderate S. mansoni infection–related ﬁ-
brosis, respectively, whereas liver patterns E and F indicate
advanced infection-related liver ﬁbrosis. Increased portal vein
diameter was deﬁned as 2 SD above standard reference
measurements developed fromhealthy, uninfected childrenof
corresponding height in other endemic countries.28,29
Statistical analysis. Subjects were considered positive for
infection if at least one eggwas found on any of the Kato–Katz
slides prepared from their stool specimens. The mean egg
count for the six slides was calculated and multiplied by 24 to
estimate the child’s infection intensity in eggs per gram of
stool (epg). In Kenya, egg counts were truncated at 42 eggs
per slide, indicating a heavy infection having > 1,000 epg. In
cases where specimens were missing, the calculation was
performed using data from the available slides for each af-
fected child. Consistent with the WHO guidelines,4 infected
individuals with < 100 epg were considered to have light in-
fections, those with 100–399 epg to have moderate intensity
infections, and individuals with ³ 400 epg to have severe-
infections. For the present analysis, group-wise infection in-
tensity is reported in two different ways: 1) as the arithmetic
mean of epg for all tested persons, including those with epg =
zero (mean intensity for the entire cohort) and2) as themeanof
epg only for those children found to be egg positive (mean
intensity among those infected). Absolute change in preva-
lence from Year 1 to Year 5 was calculated as (prevalence in
Year 5 minus prevalence in Year 1). For example, a 20% de-
crease in prevalence in a location having a starting prevalence
of 40% means a decline to 20% prevalence, whereas in a
location with a starting prevalence of 80%, 20% prevalence
reduction would result in a prevalence of 60%. Relative per-
cent change in prevalence from Year 1 to Year 5 was calcu-
lated as ([prevalence in Year 5 minus prevalence in Year 1/
prevalence Year 1] × 100). This would determine the relative
percent change in prevalence, regardless of starting preva-
lence. Using this method, the starting prevalence would in-
ﬂuence the level of decline, such that going from 80% to 60%
would be a 25%drop in prevalence, whereas going from 40%
to 20% would be classiﬁed as a 50% decline in prevalence.
Summary statistics were calculated to compare the char-
acteristics of the combined cohort in terms of demography,
infection status, andmorbidity markers and to compare those
who had only Year 1 data (i.e., those lost to follow-up) with
those who remained in the cohort in Year 5. Following the
SCORE project’s a priori statistical analysis plan, linear or
generalized linear mixed effect models adjusting for village-
level clustering effects, and, where appropriate, age and
gender were used to obtain odds ratios (for binary outcomes)
and group-wise differences (for continuous outcomes) for
comparisons between study arms. Even though all villages in
the Kenyan and Tanzanian locations were selected based on
having a baseline school age prevalence of infection of ³ 25%,
because of the village-level cluster randomization design,
there were resultant imbalances in baseline infection factors
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(average prevalence and intensity) between study arms. As a
result, our ability to detect differences by treatment arm at
Year 5 was diminished. To compensate for these starting
imbalances and to better detect differences between the
two arms from Year 1 to Year 5, we also studied the in-
teraction effects of survey year with study arm on relative
changes in results for infection, infection intensity, and
morbidity markers, although adjusting for gender. For
outcome variables missing in 10% or more children from
the entire cohort, analyses initially conducted for complete
cases were later repeated with missing data imputed using
multiple imputation procedures.10,30 Results obtained
from the multiply-imputed datasets were compared with
those generated from the original dataset. Statistical
analyses were performed using SAS version 9.4 (SAS In-
stitute Inc., Cary, NC). An α = 0.05 level was used for sig-
niﬁcance of all statistical tests and for the conﬁdence
interval calculations.
RESULTS
Combined cohort characteristics. Table 1 describes the
characteristics of participants in Year 1 at baseline, and in
Year 5 after 4 years of intervention. Of 1,374 individuals
who were enrolled at baseline in the combined cohort,
891 (64.5%) participated in Year 5 data collection. In
aggregate, girls comprised 55% of participants in the
annual CWT arm and 50% of participants in the biennial
SBT arm at both baseline and Year 5 (difference not sig-
niﬁcant [NS], P = 0.118). At baseline (Year 1), 72% of
participants in the annual CWT arm and 57% in the bi-
ennial SBT arm were infected (Figure 2), and this differ-
ence was statistically signiﬁcant (P < 0.0001). Mean
intensities for the entire cohort at baseline were 148 epg
for children in the annual CWT arm, which is signiﬁcantly
higher than the 110 epg for those in the biennial SBT arm
(Figure 3). Baseline individual-level intensity, including
only those children whowere egg positive, was 206 epg in
the annual CWT arm and 194 epg in the biennial SBT arm
(difference NS).
By Year 5, prevalence had declined to 43% in the annual
CWT arm and 48% in the biennial SBT arm (difference NS,
Figure 2). Both cohort-level and individual-level infection
intensities declined in both arms, with relatively higher egg-
reduction rates in the annual CWT arm (Figure 3). Baseline
characteristics of lost-to-follow-up subjects were similar to
those of children who had remained in the study through Year
5 (Table 1).
The absolute differences in prevalence values between
Year 5 and Year 1 in the annual CWT arm and in the biennial
SBT arm were 29 (CI95% = 22.6–35.3) and 8.4 (CI95% =
1.8–15.1) percentage points, and the relative changes in
prevalence for the two arms were 40.2% and 14.8% re-
ductions, respectively. Absolute differences for full cohort
mean intensity for treatment subgroupswere 107.4 (CI95% =
76.2–138.6) epg in the annual CWT arm and 49.8 (CI95% =
18.4–81.3) epg in the biennial SBT arm, with corresponding
relative reductions of 72.4% and 45.4%. Absolute changes
in individual-level intensity of egg-positive children in the
two arms were 110.8 (CI95% = 57.7–163.9) epg and 69.5
(CI95% = 13–126) epg, and their relative changes were
53.8% and 35.9%, respectively. In each category, the
TABLE 1
Baseline and Year 5 characteristics of cohort participants (children with data both in Year 1 and Year 5) and baseline characteristics of those lost to
follow-up, by arm
Year 1, cohort children Year 5, cohort children
Year 1 data for children lost to follow-up
in Year 5
Annual CWT arm* Biennial SBT arm* Annual CWT arm Biennial SBT arm Annual CWT arm Biennial SBT arm
Number of children 450 441 450 441 220 263
Percent female 54.9% 49.7% 54.9% 49.7% 54.1% 50.2%
Age (years) (SD) 7.4 (0.5) 7.6 (0.5) 11.5 (0.5) 11.6 (0.5) 7.5 (0.5) 7.6 (0.5)
No. tested for schistosomiasis 446 438 406 413 217 252
No. infected 320 248 175 199 154 122
Prevalence 72.1% 56.6% 43.1% 48.2% 71% 48.4%
Full cohort arithmetic mean infection
intensity (epg)
148.4 109.7 41 59.9 144.9 113.8
Egg-positive children’s mean infection
intensity (epg)
206 193.7 95.1 124.2 204.1 235
CWT = community-wide treatment; epg = eggs per gram feces; SBT = school-based treatment.
* After the baseline (Year 1) survey, communities in the annual CWT arm received community-wide praziquantel treatment every year for four years; communities in the biennial SBT arm received
SBT every other year.
FIGURE 2. Comparison of Year 1 and Year 5 Schistosoma mansoni
prevalence for participating children in each of the combined cohort
study arms (annual community-wide treatment (CWT) vs. biennial
school-based treatment [SBT]). Dark circles indicate baseline and
Year 5 prevalence values for the annual CWT arm. Open squares in-
dicate corresponding prevalence values for the children in the biennial
SBT arm. Error bars indicate 95% CI.
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annual CWT arm subjects had greater declines in these
measures. Between Year 1 and Year 5, prevalence of heavy
infections declined from 11.1% to 1.7% in the annual CWT
arm and from 8.9% to 2.6% in the biennial SBT arm. After
adjustment for village-level clustering effects, these
between-arm differences in heavy intensity prevalence
were not signiﬁcant (Rao–Scott χ2 = 0.116, P = 0.73 for
between-arm difference in Year 1; χ2 = 1.07, P = 0.30 for
between arm difference in Year 5).
We observed a signiﬁcant increase in stunting among chil-
dren in the biennial SBT arm, and signiﬁcant decreases in
wasting prevalence in both arms over the course of the study
(Table 2). Hemoglobin levels did not change signiﬁcantly
during the study period. The prevalence of anemia remained
roughly stable between Year 1 and Year 5 in the annual CWT
arm and declined slightly, but not signiﬁcantly, in the biennial
SBT arm. Maximal oxygen uptake as estimated by ﬁtness
testing scores dropped in both arms from Year 1 to Year 5.
Among PedsQL outcomes, the total score, as well as scores
on the physical, emotional, and school subdomains, in-
creased over time in both study arms. There were signiﬁcant
Year 1 to Year 5 declines in the percentage of children with
elevated portal vein diameter in both study arms. Abnormal
liver pattern (Pattern C or higher) was rare, and no signiﬁcant
changeswere noted for this ﬁnding in either armbetweenYear
1 and Year 5.
Comparison of infection and morbidity markers be-
tween Year 1 and Year 5. Table 3 presents prevalence, in-
tensity, and the morbidity markers with statistically signiﬁcant
changes between Year 1 and Year 5 for all children in the
combined cohorts, regardless of armassignment (N=891). All
comparisons use Year 1 as the reference group. For the
combined groups, overall prevalence declined signiﬁcantly
fromYear 1 toYear 5, asdid theprevalence of heavy infections
and infection intensity. Wasting was signiﬁcantly less com-
mon, but stunting was signiﬁcantly more common in Year 5
relative to Year 1. In addition, the percentage of children with
elevated portal vein diameter values declined signiﬁcantly
fromYear 1 to Year 5.Maximal oxygen uptake as estimated by
ﬁtness testingmaxdecreased signiﬁcantly fromYear 1 toYear
5. By contrast, all the PedsQL measures increased signiﬁ-
cantly from Year 1 to Year 5.
Age-, andgender-adjustedcomparisonsbetweenstudy
arms, accounting for village-level intraclass correlation. In
this ﬁrst-stage modeling analysis of the SCORE project’s a
priori statistical analysis plan, no signiﬁcant differences were
observed between the two study arms across the range of
measured infection and morbidity markers (Table 4).
To account for the imbalances in baseline disease status, in
a secondary analysis, we next studied the interaction effects
of the survey year (Year 5 versus Year 1) and study arm (CWT
versus SBT) on relative changes in results for the cohort in-
dicators of infection andmorbidity, adjusting for gender, village-
level clustering effects, and individual Year 1 starting values
(Table 5). By this analysis, prevalence and intensity dropped
signiﬁcantly more by Year 5 in the annual CWT arm, as com-
pared with the SBT arm. Maximal oxygen uptake as estimated by
ﬁtness testingmax levelsdeclined inboth thearms, butdecreased
FIGURE 3. Comparison of Year 1 and Year 5 Schistosoma mansoni
infection intensities by the cohort study arm. Shown here are Year 1
baseline intensity values (dark bars) and 95% CI for participating
children in the two study arms receiving either annual community-
wide treatment (CWT) or biennial school-based treatment (SBT), cal-
culated either as arithmetic mean intensity for egg-positive children
(individual-level intensity, left side), or asmean intensity for all children,
including thosewith zeroeggcounts (cohort-level intensity, right side).
Corresponding values for participating children in Year 5, after MDA,
are shown by the light bars.
TABLE 2
Summary results for morbidity markers, by arm, by year
Annual CWT arm Biennial SBT arm
Year 1 Year 5 Year 1 Year 5
Body mass index: Average Z score (SD) −1.3 (1.1) −0.9 (1.1) −1 (1) −0.3 (1)
Prevalence of stunting (CI95%) 9.9% (7.1, 12.7%) 11.5% (8.4, 14.6%) 5.1% (3, 7.1%) 10.8% (7.9, 13.8%)
Prevalence of wasting (CI95%) 24.9% (20.9, 29%) 12.7% (9.5, 15.9%) 13.2% (10, 16.4%) 3.9% (2, 5.7%)
Mean hemoglobin gm/dL (SD) 12 (2.3) 11.7 (1.8) 11.9 (2.1) 12.1 (1.8)
Prevalence of anemia (CI95%) 42.6% (37.9, 47.2%) 45.8% (40.8, 50.7%) 42.9% (38.2, 47.6%) 37.9% (33.3, 42.6%)
Mean VO2 max score (SD) 49.2 (3.3) 43.5 (6.2) 49.2 (3.4) 44.4 (5.8)
Mean pediatric quality of life inventory scores
Total score (SD) 83.6 (12.4) 91.9 (11.6) 85 (14.3) 90.7 (11.8)
Physical (SD) 88.9 (14.9) 94.5 (11.2) 88.2 (19.7) 93.2 (15.1)
Emotional (SD) 71.9 (15.1) 89.8 (16.1) 77.1 (16.8) 87.1 (18.2)
Social (SD) 90.4 (16.4) 91.9 (16.4) 91.3 (18.6) 93.1 (14.1)
School (SD) 80 (16.3) 90.7 (13.7) 81.6 (18.6) 89.2 (14)
Prevalence of increased portal vein
diameter (CI95%)
10.8% (7.9, 13.7%) 1.7% (0.4, 2.9%) 9% (6.3, 11.7%) 1.2% (0.2, 2.2%)
Ultrasound pattern prevalence
Pattern B (CI95%) 16.6% (13, 20.1%) 11.4% (7.5, 13.4%) 8.9% (6.2, 11.6%) 11.7% (7.8, 13.7%)
Pattern C or higher (CI95%) 0.7% (0.1, 2%) 0.5% (0, 1.7%) 0.9% (0.3, 2.4%) 0.7% (0.1, 2%)
CWT = community-wide treatment; SBT = school-based treatment; VO2 max = maximal oxygen uptake as estimated by ﬁtness testing.
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signiﬁcantly more in the annual CWT arm than in the biennial SBT
arm.Bycontrast, changesof total PedsQLscoreand its emotional
and school subdomains were all signiﬁcantly positive from Year 1
to Year 5 for both the arms, but children in the annual CWT arm
gained more. Not shown, changes in prevalence of anemia,
wasting, stunting, or increased portal vein diameter were not sta-
tistically different between the arms (see Supplemental Table 1).
Sensitivity analysis for effects of missing data using
multiple imputation. The potential impact of missing data
was investigated, and the result from the imputed datasets did
not differ signiﬁcantly.
DISCUSSION
This combined cohort analysis of morbidity outcomes in
Kenya and Tanzania10,12,14 demonstrates that regular treatment
of schoolchildren is associated with reductions in both
S.mansoni infectionprevalenceandmean infection intensity. For
schoolchildren who were followed to 11–12 years of age,
participation in either annual CWTor biennial SBTprogramswas
also associatedwith reductions in the prevalence ofwasting and
portal vein dilation. Health-related quality-of-life scores showed
improvement in both treatment groups. These ﬁndings suggest
cumulative beneﬁts from regular preventive treatment (whether
CWT or SBT) can be obtained in S. mansoni–endemic commu-
nities that are similar to those included in this study. Reduction in
portal vein dilation, the study pathology most closely tied to
adverse outcomes from intestinal schistosomiasis, is of partic-
ular importance. In the absence of an untreated concurrent
control group, we cannot deﬁnitively ascribe these beneﬁts to
treatment intervention. However, prolonged nontreatment was
considered tobeanunethical choiceat the timeof studydesign.7
It is thus possible that unmeasured confounding factors such as
food insecurity and intercurrent infections or reinfections may
have inﬂuenced the observed study outcomes.
Because the overall research trial used cluster-based ran-
dom assignment of villages to treatment regimens, there were
differences in baseline S. mansoni prevalence and infection
TABLE 3
Outcomes with signiﬁcant changes from Year 1 to Year 5, for both study arms combined
Odds ratio
(reference = Year 1) CI95% P-value
Infection prevalence 0.36 0.28, 0.47 < 0.0001
Prevalence of heavy infections 0.22 0.14, 0.36 < 0.0001
Wasting 0.37 0.27, 0.50 < 0.0001
Stunting 1.56 1.10, 2.21 0.02
Elevated portal vein diameter 0.13 0.07, 0.25 < 0.0001
Average change CI95% P-value
VO2 (mL/kg/min) −5.5 −5.9, −5.2 < 0.0001
Pediatric quality of life inventory
Total score 8 7, 9.1 < 0.0001
Physical 6.2 4.8, 7.6 < 0.0001
Emotional 14.8 13.3, 16.3 < 0.0001
Social 2.9 1.5, 4.3 < 0.0001
School 10.1 8.7,11.5 < 0.0001
Coefﬁcient CI95% P-value
Mean cohort-level
infection intensity (epg)
−0.92 −0.93, −0.91 < 0.0001
epg = S. mansoni eggs per gram feces; VO2 max = maximal oxygen uptake as estimated by ﬁtness testing.
TABLE 4
Age- and gender-adjusted CWT-arm participant likelihood of study morbidity at Year 5, using the SBT-arm participants as reference
Odds ratio (reference = the biennial school-based
treatment arm) CI95% P-value
Infection prevalence 0.77 0.19, 3.06 0.70
Wasting 2.73 0.94, 7.90 0.06
Stunting 1.19 0.57, 2.47 0.65
Anemia 1.26 0.51, 3.12 0.62
Increased PVD 1.40 0.25, 7.72 0.70
Arm difference CI95% P-value
VO2 (mL/kg/min) −0.5 −4.8, 3.7 0.80
Pediatric quality of
life inventory
Total score 0.7 −7.1, 8.5 0.86
Physical 0.7 −5.6, 7 0.82
Emotional 1.8 −9.6, 13.2 0.76
Social −1.4 −9.3, 6.6 0.73
School 1.4 −6.2, 8.9 0.73
Coefﬁcient CI95% P-value
Mean cohort-level
intensity (epg)
−0.1 −1.9, 1.7 0.92
CWT = community-wide treatment; epg = S. mansoni eggs per gram feces; PVD = portal vein diameter; VO2 max, maximal oxygen uptake as estimated by ﬁtness testing.
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intensity between the two arms in our analysis, and this initially
obscured the signiﬁcance of between-arm differences in
outcomes, that is, between children in villages receiving an-
nual CWT and those receiving biennial SBT. After adjusting for
the higher starting prevalence and intensity, it was noted that
annual CWT led to signiﬁcantly greater decreases in infection
prevalence and intensity than did biennial SBT. In addition,
children in annual CWT villages gained signiﬁcantly more in
emotional well-being and school satisfaction.
The reasons for persistent morbidity despite MDA are likely
to be multifactorial. Location-related variations in reinfection
risk, in growth indices, in anemia, and in ﬁtness have been
previously demonstrated between the Kenyan and Tanzanian
areas included in this study. There were also signiﬁcant dif-
ferences in sanitation knowledge and practices and in intake
of high-quality protein foods.31 Unfortunately, as children
grow up in resource-limited areas, cumulative growth deﬁcits
are a common ﬁnding,32,33 and our combined studies’ out-
comes are in accord with that frequent observation.
Twenty-meter SRT–based VO2 scores have been shown to
decline as children age into adolescence, with girls more af-
fected than boys.19,21 The higher prevalence of stunting and
wasting in the annual CWT arm, both at baseline and in Year
5, may have contributed to the observed between-arm dif-
ference in VO2max results, which are affected both by stature
and muscle mass. Although socioeconomic status can affect
PedsQL scores,24 the average scoring does not appear to
change as a function of age, either for healthy or chronically ill
childrenandadolescents.24 The improvements reported inour
cohort analysis are thus unlikely to reﬂect an age effect and
maymore likely reﬂect the impact of continued participation in
preventive treatment of chronic schistosomiasis.5
There are several limitations to our study. Our study pop-
ulations live in areas highly endemic for malaria and soil-
transmitted helminths, which likely had an impact on anemia
outcomes through blood loss, anemia of chronic in-
ﬂammation,34 and intermittent episodes of symptomatic
malaria associated with hemolysis.14,31 Although both the
Kenyan and Tanzanian sites were tested for the presence of
coinfection with malaria, the sensitivity of the techniques
they used (blood smear versus rapid diagnostic tests) and
timing of their testing (Y5 versus Y3) were sufﬁciently differ-
ent so that we were unable to estimate the impact of malarial
infection across the combined cohort. Perhaps, the most
critical study limitation was the parent studies’ village-level
cluster randomization design, which provided only a limited
number of evaluation units (i.e., villages) available for analy-
sis.10 Village-to-village variation in response to MDA
schedules proved to be much higher than anticipated in the
initial design of the SCORE studies,11,35 which likely ob-
scured the differences in MDA impact by the study arm.9,11
Therefore, a relative strength of our analysis is the inclusion
of a somewhat larger number of study locations, with ex-
tended analysis to adjust for differing baseline prevalence
between the two study arms. Measurement of infection
status only in Year 1 and in Year 5 may not have adequately
captured cumulative parasite exposure. A child who tested
negative at baseline and in Year 5 could still have spent
several years repeatedly infected with S. mansoni between
the beginning and the end of the study, despite periodicMDA
treatments and could have accrued signiﬁcant residual
morbidity without evidence of active infection in Year 5.
The current WHO strategy for reduction in schistosomiasis
morbidity is based on achieving reductions in the community-
level prevalence of heavy infections among school-age chil-
dren.6 Few children in our cohorts had heavy infections by the
WHO deﬁnition (³ 400 epg in feces), so we could not assess
whether reduction in intensity changed individual morbidity
risk. Nevertheless, even though most of the combined cohort
children were not heavily infected, in aggregate, they
appeared to beneﬁt signiﬁcantly from their community’s par-
ticipation in MDA. It is not clear, however, whether these im-
provements will remain in effect if MDA is stopped and
exposure to infection continues.
Larger studies are currently being designed to better deﬁne
the community-level infection prevalence and intensity levels
below which morbidity associated with schistosomiasis can-
not be detected. These studies will more fully measure the
spectrum of schistosomiasis-related morbidities, and control
for cofactors that contribute to their occurrence. Such
TABLE 5
Gender-adjusted comparison of arm-speciﬁc changes in infection andmorbidity outcomes fromYear 1 to Year 5, including interaction term added
to account for differences in starting values between groups
Outcomes Predictors Coefﬁcient CI95% P-value
Infection prevalence Year 5 −0.4 −0.8, −0.1 0.01
Annual CWT 0.6 −0.7, 1.9 0.35
Annual CWT × Year 5 −1.1 −1.5, −0.6 < 0.0001
Intensity (epg) Year 5 −0.59 −0.61, −0.58 < 0.0001
Annual CWT 0.7 −1.1, 2.6 0.41
Annual CWT × Year 5 −0.68 −0.70, −0.65 < 0.0001
VO2 max Year 5 −5 −5.5, −4.5 < 0.0001
Annual CWT 0.4 −2.6, 3.4 0.81
Annual CWT × Year 5 −1 −1.7, −0.3 0.004
PedsQL total Year 5 6.1 4.6, 7.6 < 0.0001
Annual CWT −2.6 −8.9, 3.6 0.40
Annual CWT × Year 5 3.9 1.8, 6 0.0003
PedsQL emotional Year 5 10.2 8.1, 12.3 < 0.0001
Annual CWT −6.6 −13.2, −0.1 0.05
Annual CWT × Year 5 9.4 6.4, 12.4 < 0.0001
PedsQL school Year 5 7.7 5.8, 9.7 < 0.0001
Annual CWT −2.7 −9.3, 3.9 0.43
Annual CWT × Year 5 4.9 2.1, 7.7 0.0007
CWT = community-wide treatment; epg = S. mansoni eggs per gram feces; PedsQL = pediatric quality of life inventory; VO2 max = maximal oxygen uptake as estimated by ﬁtness testing.
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additional data should be extremely helpful as the WHO re-
ﬁnes its global programmatic guidelines for control of Schis-
tosoma infection–related morbidity.
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